USA flag logo/image

An Official Website of the United States Government

Company Information:

Company Name:
BIOMEDICA MANAGEMENT CORP.
Address:
760 Parkside Ave., #304
BROOKLYN, NY
Phone:
(212) 719-4799
URL:
N/A
EIN:
134073473
DUNS:
146587345
Number of Employees:
7
Woman-Owned?:
No
Minority-Owned?:
No
HUBZone-Owned?:
No

Commercialization:

Has been acquired/merged with?:
N/A
Has had Spin-off?:
N/A
Has Had IPO?:
N/A
Year of IPO:
N/A
Has Patents?:
N/A
Number of Patents:
N/A
Total Sales to Date $:
$ 0.00
Total Investment to Date $
$ 0.00
POC Title:
N/A
POC Name:
N/A
POC Phone:
N/A
POC Email:
N/A
Narrative:
N/A

Award Totals:

Program/Phase Award Amount ($) Number of Awards
SBIR Phase I $583,280.00 6
SBIR Phase II $3,697,746.00 3

Award List:

ANTI-SELECTIN BLOCKER FOR ORGAN ISCHEMIC INJURY

Award Year / Program / Phase:
2002 / SBIR / Phase I
Award Amount:
$107,000.00
Agency:
HHS
Principal Investigator:
Abstract:
Description (provided by applicant): Drugs currently available for the treatment of ischemic (lack of blood supply) conditions are not satisfactory. Since selectins have a primordial role in the development of ischemia, we have proposed the use of a recently discovered anti-selectin blocker… More

Anti-Selectin Blocker for Liver Ischemic Injury

Award Year / Program / Phase:
2004 / SBIR / Phase II
Award Amount:
$719,044.00
Agency:
HHS
Principal Investigator:
Abstract:
DESCRIPTION (provided by applicant): Our objective is to develop a new treatment that will prevent or decrease the tissue damage caused by neutrophil infiltration after ischemia/reperfusion (I/R), which occurs as the result of stroke, coronary ischemia, trauma and other related conditions.… More

Anti-ischemic Resuscitation Fluid

Award Year / Program / Phase:
2007 / SBIR / Phase I
Award Amount:
$104,178.00
Agency:
HHS
Principal Investigator:
Abstract:
DESCRIPTION (provided by applicant): Inflammation after ischemia and reperfusion (I/R) injury secondary to hemorrhagic shock is responsible for significant mortality and morbidity in the United States. Available intravenous fluids administered at the incid ent scene to treat hypovolemic shock do not… More

Intracavitary Hemostatic Agent for Non-compressible Hemorrhage

Award Year / Program / Phase:
2007 / SBIR / Phase I
Award Amount:
$103,148.00
Agency:
HHS
Principal Investigator:
Abstract:
DESCRIPTION (provided by applicant): Hemorrhage resulting from traumatic injuries is a major cause of death in accidents, and the primary cause of death on the battlefield. Early and effective hemorrhage control can save more lives than any other measure. Tissue adhesives and sealants have been… More

Tissue Sealant for Intracavitary Non-compressible Hemorrhage

Award Year / Program / Phase:
2008 / SBIR / Phase I
Award Amount:
$98,957.00
Agency / Branch:
DOD / DARPA
Principal Investigator:
Abstract:
ClotFoam is a novel crosslinked polymer designed to stop hemorrhage without compression in severe wounds outside the operating room. ClotFoam's ability to promote hemostasis in cases severe bleeding is based on the physical and coagulation properties of a fibrin sealant embedded in a gelatin support… More

Immunomodulation of Sophorolipids in Sepsis

Award Year / Program / Phase:
2008 / SBIR / Phase I
Award Amount:
$99,999.00
Agency:
HHS
Principal Investigator:
Abstract:
DESCRIPTION (provided by applicant): Microbial sophrolipids are a new a class of membrane-derived glycolipids that have wide ranging potential in clinical practice. We have demonstrated that sophorolipids possess remarkable anti-inflammatory effects in var ious inflammatory conditions including… More

Clinical Development of Hemostatic Agent ClotFoam for Severe Hemorrhage

Award Year / Program / Phase:
2009 / SBIR / Phase II
Award Amount:
$1,001,006.00
Agency:
HHS
Principal Investigator:
Maja Nowakowski
Abstract:
DESCRIPTION (provided by applicant): Hemorrhage resulting from traumatic injuries is a major cause of death in accidents, and the primary cause of death on the battlefield. Over 40% of the trauma cases admitted at hospitals in the USA, are due to road traf fic accidents. Hemorrhage is the primary… More

non-compressible Biodegradable Hemostatic Agent

Award Year / Program / Phase:
2009 / SBIR / Phase I
Award Amount:
$69,998.00
Agency / Branch:
DOD / ARMY
Principal Investigator:
Maya Nowakowski, Director of Research
Abstract:
we propose to determine the biocompatibility of ClotFoam and enhance its hemostastic and non-compressible sealing effects against a severe parenchymial hemorrhage caused by a wound grade V affecting major vessels, which represents a lethal case in combat injuries. The strategy is to develop a… More

Clinical Development of Hemostatic Agent ClotFoam for Severe Hemorrhage

Award Year / Program / Phase:
2012 / SBIR / Phase II
Award Amount:
$1,977,696.00
Agency:
HHS
Principal Investigator:
Maja Nowakowski – 718-270-2749
Abstract:
DESCRIPTION (provided by applicant): ClotFoam(R) , is a novel adhesive sealant composition and second-generation hemostatic agent. This biological agent was designed to arrest moderate to severe blood loss arising from intracavitary traumatic injury orintraoperative hemorrhage without… More